TG Therapeutics, Inc. (NASDAQ:TGTX) Expected to Post FY2026 Earnings of $1.60 Per Share

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - B. Riley reduced their FY2026 earnings estimates for shares of TG Therapeutics in a note issued to investors on Tuesday, April 30th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will earn $1.60 per share for the year, down from their prior forecast of $1.81. B. Riley currently has a "Buy" rating and a $29.00 target price on the stock. The consensus estimate for TG Therapeutics' current full-year earnings is ($0.11) per share. B. Riley also issued estimates for TG Therapeutics' FY2027 earnings at $2.62 EPS and FY2028 earnings at $3.54 EPS.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03. The firm had revenue of $43.97 million during the quarter, compared to the consensus estimate of $40.06 million. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. During the same quarter in the previous year, the company posted ($0.39) earnings per share.

Several other equities analysts have also recently weighed in on the company. HC Wainwright restated a "buy" rating and set a $45.00 price objective on shares of TG Therapeutics in a research note on Thursday, April 18th. The Goldman Sachs Group boosted their price target on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Thursday, February 29th. StockNews.com lowered shares of TG Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, February 24th. LADENBURG THALM/SH SH restated a "buy" rating and issued a $39.00 target price on shares of TG Therapeutics in a research note on Thursday, April 18th. Finally, JPMorgan Chase & Co. reiterated an "overweight" rating and set a $25.00 price target on shares of TG Therapeutics in a report on Thursday, April 18th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $29.00.

TG Therapeutics Stock Up 16.3 %

Shares of NASDAQ:TGTX traded up $2.22 during midday trading on Wednesday, hitting $15.88. 18,583,064 shares of the company's stock were exchanged, compared to its average volume of 4,285,143. TG Therapeutics has a 12 month low of $6.46 and a 12 month high of $35.67. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.92 and a quick ratio of 5.18. The stock has a 50 day moving average price of $15.07 and a 200-day moving average price of $14.32. The company has a market cap of $2.45 billion, a PE ratio of 769.38 and a beta of 2.30.

Insider Buying and Selling

In related news, Director Laurence N. Charney sold 22,000 shares of the company's stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total transaction of $351,340.00. Following the sale, the director now directly owns 215,229 shares in the company, valued at approximately $3,437,207.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 9.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in TGTX. Vanguard Group Inc. raised its position in shares of TG Therapeutics by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 13,670,944 shares of the biopharmaceutical company's stock worth $233,500,000 after buying an additional 199,770 shares in the last quarter. Wellington Management Group LLP increased its stake in TG Therapeutics by 1.4% in the 4th quarter. Wellington Management Group LLP now owns 3,139,764 shares of the biopharmaceutical company's stock worth $53,627,000 after acquiring an additional 43,290 shares during the last quarter. Opaleye Management Inc. raised its holdings in shares of TG Therapeutics by 17.2% in the 4th quarter. Opaleye Management Inc. now owns 2,215,000 shares of the biopharmaceutical company's stock valued at $37,832,000 after acquiring an additional 325,000 shares in the last quarter. Schonfeld Strategic Advisors LLC boosted its position in shares of TG Therapeutics by 164.5% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 1,367,400 shares of the biopharmaceutical company's stock valued at $11,431,000 after acquiring an additional 850,507 shares during the last quarter. Finally, 683 Capital Management LLC purchased a new position in shares of TG Therapeutics during the third quarter worth about $11,286,000. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.